DEXLEVO
12.5.2022 04:31:14 CEST | Business Wire | Press release
The aesthetic and medical device company DEXLEVO attended the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco and explained its products to the visitors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005974/en/
The world's first fully liquid PCL (polycaprolactone) injectable, GOURI developed by DEXLEVO, an aesthetic and medical device company, was the first in Asia to be chosen as Best Injectable in the category at the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco from March 31 to April 2, 2022.
AMWC is one of the world's most prestigious aesthetic and anti-aging congresses. More than 20,000 visitors from more than 200 countries worldwide, including dermatologists, attend the event every year to share the latest trends in aesthetic and anti-aging products and industry trends.
DEXLEVO launched GOURI, the world's first fully liquid PCL injectable, at the AMWC in 2021. Attending AMWC for the second year, it won the Best Injectable award for the first time as an Asian company at the AMWC Awards, having its unique technology and products recognized on the world stage. For the AMWC Awards, the AMWC Committee reviews and chooses the candidate products, judged by votes from dermatologists and industry workers around the world. At this year's review, DEXLEVO was nominated alongside prominent global beauty companies such as Allergan, Merz, Fillmed, and Aptos, proving its competence in the global market.
More than 150 doctors and companies visited DEXLEVO's booth and showed great interest in GOURI, which provides a fundamental solution to anti-aging.
Under the theme of "1st Liquid PCL-What, When, Why?", Mexican dermatologist Dr. Arturo Vela said, "The beauty market now wants naturalness. DEXLEVO's GOURI is the world's first fully liquid PCL injectable and the safest anti-aging product that meets consumer needs." Croatian dermatologist Dr. Dinko Kaliterna gave a treatment lecture at the congress under the theme "Skin Rejuvenation with Liquid PCL," saying, "GOURI is safer than competing products and its treatment is very convenient. Also, patient’s satisfaction with the procedure is high due to the natural collagen regeneration effect."
An official from DEXLEVO said, "As the trend in the beauty market changes, more companies are showing interest compared to last year's AMWC. Since the global market is showing increasing interest in GOURI, we plan to support marketing to become a leader in anti-aging products."
DEXLEVO's GOURI is the world's first fully liquid type PCL injectable of polycaprolactone (PCL), a biodegradable polymer material, that spreads naturally throughout the face and around the eyes when injected into the skin, forming a three-dimensional matrix and causing collagen production.
With the launch of AMWC in September 2021, DEXLEVO is selling and contracting GOURI in more than 40 countries and will participate as a platinum sponsor in IMCAS 2022, to be held in Paris in June this year, to accelerate marketing activities and expand the global market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005974/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom